checkAd
    Startseite > Aktien > Arvinas > Nachrichten
    Arvinas Aktie
    32,68
     
    USD
    +1,78 %
    +0,57 USD
    Letzter Kurs 02:00:00 Nasdaq
    32,68
     
    USD
    300 STK
    Geldkurs 17.05.24
    32,69
     
    USD
    1.000 STK
    Briefkurs 17.05.24
    ISIN: US04335A1051 · WKN: A2N6VP · SYM: ARVN · USA

    Neueste Nachrichten

    Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)
    16.05.24 · globenewswire · Arvinas
    Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
    09.05.24 · globenewswire · Arvinas
    Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
    07.05.24 · globenewswire · Arvinas
    Arvinas to Present at Upcoming Investor Conferences
    02.05.24 · globenewswire · Arvinas
    Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
    24.04.24 · globenewswire · Arvinas
    Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
    11.04.24 · globenewswire · Arvinas
    Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
    18.03.24 · globenewswire · Arvinas
    Arvinas to Participate in Upcoming Investor Conferences
    04.03.24 · globenewswire · Arvinas
    Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    27.02.24 · globenewswire · Arvinas
    Arvinas Announces Chief Financial Officer Transition
    20.02.24 · globenewswire · Arvinas
    Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC Protein Degrader for Neurodegenerative Disease
    20.02.24 · globenewswire · Arvinas
    Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
    06.02.24 · globenewswire · Arvinas